Payment overview · 2025
General Payments
$562.76
25 reported records · 12 companies
Healthcare provider profile · identity verified
Charles E Brock, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CLEVELAND, MS · NPI 1689761280
Verified facts
What the public records show
CMS Open Payments records show Charles E Brock, M.D. received $562.76 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 316 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viibryd by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 618 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 361 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 335 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 284 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 465 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $188.71 | 33.5% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.60 | 10.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.79 | 8.7% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.37 | 6.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.68 | 6.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.63 | 6.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.27 | 6.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.78 | 6.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.04 | 5.5% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $23.58 | 4.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.97 | 3.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.34 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $543.46 | 24 |
| Education | $19.30 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $104.06 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $64.82 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.79 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.79 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.21 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 618 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 316 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 335 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 284 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
316 | 74 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
94 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
618 | 124 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
361 | 61 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
335 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
284 | 50 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
465 | 87 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1032 | 293 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1010 | 218 |
| Atorvastatin Calcium | Atorvastatin Calcium | 867 | 227 |
| Potassium Chloride | Potassium Chloride | 739 | 183 |
| Metoprolol Succinate | Metoprolol Succinate | 725 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 694 | 185 |
| Furosemide | Furosemide | 693 | 186 |
| Gabapentin | Gabapentin | 678 | 150 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 660 | 122 |
| Farxiga | Dapagliflozin Propanediol | 618 | 124 |
| Omeprazole | Omeprazole | 541 | 157 |
| Pantoprazole Sodium | Pantoprazole Sodium | 532 | 143 |
| Diclofenac Sodium | Diclofenac Sodium | 519 | 153 |
| Eliquis | Apixaban | 465 | 87 |
| Metformin Hcl Er | Metformin Hcl | 447 | 127 |
| Losartan Potassium | Losartan Potassium | 432 | 107 |
| Clopidogrel | Clopidogrel Bisulfate | 392 | 91 |
| Simvastatin | Simvastatin | 383 | 99 |
| Nifedipine Er | Nifedipine | 375 | 101 |
| Quetiapine Fumarate | Quetiapine Fumarate | 364 | 49 |
| Jardiance | Empagliflozin | 361 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 357 | 88 |
| Metformin Hcl | Metformin Hcl | 348 | 86 |
| Mounjaro | Tirzepatide | 335 | 60 |
| Linzess | Linaclotide | 316 | 74 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 305 | 87 |
| Famotidine | Famotidine | 291 | 74 |
| Montelukast Sodium | Montelukast Sodium | 287 | 76 |
| Donepezil Hcl | Donepezil Hcl | 285 | 72 |
| Ozempic | Semaglutide | 284 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 282 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 266 | 79 |
| Tizanidine Hcl | Tizanidine Hcl | 252 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 251 | 63 |
| Meloxicam | Meloxicam | 239 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 62 |
| Sertraline Hcl | Sertraline Hcl | 223 | 43 |
| Carvedilol | Carvedilol | 219 | 53 |
| Ezetimibe | Ezetimibe | 206 | 65 |
| Lisinopril | Lisinopril | 206 | 52 |
| Celecoxib | Celecoxib | 202 | 47 |
| Chlorthalidone | Chlorthalidone | 201 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 201 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 201 | 42 |
| Trazodone Hcl | Trazodone Hcl | 199 | 49 |
| Valsartan | Valsartan | 193 | 53 |
| Spironolactone | Spironolactone | 190 | 46 |
| Alprazolam | Alprazolam | 189 | 43 |
| Tramadol Hcl | Tramadol Hcl | 188 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 173 | 56 |
| Memantine Hcl | Memantine Hcl | 173 | 34 |
| Allopurinol | Allopurinol | 169 | 42 |
| Divalproex Sodium | Divalproex Sodium | 167 | 23 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 167 | 28 |
| Clonazepam | Clonazepam | 163 | 35 |
| Novolog Flexpen | Insulin Aspart | 154 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 145 | 55 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 143 | 40 |
| Risperidone | Risperidone | 141 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 141 | 47 |
| Tresiba Flextouch U-200 | Insulin Degludec | 137 | 28 |
| Atenolol | Atenolol | 134 | 30 |
| Entresto | Sacubitril/Valsartan | 133 | 25 |
| Fenofibrate | Fenofibrate | 133 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 131 | 38 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 131 | 91 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 130 | 25 |
| Lansoprazole | Lansoprazole | 129 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 128 | 76 |
| Oxycodone Hcl | Oxycodone Hcl | 127 | 20 |
| Mirtazapine | Mirtazapine | 119 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 117 | 32 |
| Fluconazole | Fluconazole | 115 | 57 |
| Levetiracetam | Levetiracetam | 115 | 22 |
| Methylprednisolone | Methylprednisolone | 115 | 93 |
| Prednisone | Prednisone | 111 | 65 |
| Benztropine Mesylate | Benztropine Mesylate | 110 | 18 |
| Cefdinir | Cefdinir | 110 | 88 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 108 | 24 |
| Clonidine | Clonidine | 106 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 106 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 22 |
| Bupropion Xl | Bupropion Hcl | 101 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 30 |
| Topiramate | Topiramate | 100 | 17 |
| Xarelto | Rivaroxaban | 98 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 97 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 95 | 36 |
| Synthroid | Levothyroxine Sodium | 94 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 18 |
| Pregabalin | Pregabalin | 89 | 20 |
| Irbesartan | Irbesartan | 88 | 22 |
| Buspirone Hcl | Buspirone Hcl | 87 | 15 |
| Methocarbamol | Methocarbamol | 87 | 35 |
| Amiodarone Hcl | Amiodarone Hcl | 86 | 28 |
| Ibuprofen | Ibuprofen | 85 | 33 |
| Myrbetriq | Mirabegron | 84 | 15 |
| Cilostazol | Cilostazol | 83 | 20 |
| Clonidine Hcl | Clonidine Hcl | 83 | 17 |
| Valacyclovir | Valacyclovir Hcl | 82 | 28 |
| Finasteride | Finasteride | 81 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 79 | 21 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 79 | 17 |
| Estradiol | Estradiol | 78 | 21 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 77 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 77 | 31 |
| Etodolac | Etodolac | 75 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 75 | 27 |
| Tradjenta | Linagliptin | 75 | 14 |
| Alendronate Sodium | Alendronate Sodium | 74 | 21 |
| Bydureon Bcise | Exenatide Microspheres | 74 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 21 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 74 | 12 |
| Baclofen | Baclofen | 73 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 62 |
| Trulicity | Dulaglutide | 68 | 12 |
| Haloperidol | Haloperidol | 67 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 64 | suppressed |
| Lovastatin | Lovastatin | 64 | 13 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 64 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 17 |
| Aripiprazole | Aripiprazole | 61 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 61 | 13 |
| Megestrol Acetate | Megestrol Acetate | 60 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 18 |
| Promethazine Hcl | Promethazine Hcl | 58 | 16 |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Glimepiride | Glimepiride | 56 | 16 |
| Ondansetron Odt | Ondansetron | 56 | 33 |
| Kerendia | Finerenone | 55 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 23 |
| Vascepa | Icosapent Ethyl | 54 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 53 | 17 |
| Ramipril | Ramipril | 53 | 12 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 53 | 13 |
| Glyxambi | Empagliflozin/Linagliptin | 52 | suppressed |
| Mitigare | Colchicine | 52 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 51 | 16 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 51 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 44 |
| Humalog Kwikpen U-100 | Insulin Lispro | 50 | 12 |
| Lactulose | Lactulose | 50 | suppressed |
| Nitroglycerin | Nitroglycerin | 50 | 27 |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 49 | 34 |
| Naproxen | Naproxen | 48 | 13 |
| Colchicine | Colchicine | 47 | 15 |
| Dutasteride | Dutasteride | 47 | 11 |
| Azelastine Hcl | Azelastine Hcl | 46 | 21 |
| Colestipol Hcl | Colestipol Hcl | 46 | 13 |
| Doxepin Hcl | Doxepin Hcl | 44 | 11 |
| Propranolol Hcl | Propranolol Hcl | 44 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 22 |
| Sotalol | Sotalol Hcl | 42 | suppressed |
| Mupirocin | Mupirocin | 41 | 27 |
| Ranolazine Er | Ranolazine | 41 | suppressed |
| Eszopiclone | Eszopiclone | 40 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | 12 |
| Azithromycin | Azithromycin | 39 | 32 |
| Primidone | Primidone | 39 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 39 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 36 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 36 | 14 |
| Olanzapine | Olanzapine | 35 | suppressed |
| Levemir Flexpen | Insulin Detemir | 34 | 16 |
| Telmisartan | Telmisartan | 34 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 26 |
| Indapamide | Indapamide | 32 | suppressed |
| Novolog | Insulin Aspart | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Metronidazole | Metronidazole | 30 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 17 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Nystatin | Nystatin | 29 | 16 |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 28 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 27 |
| Rexulti | Brexpiprazole | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 11 |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Ibu | Ibuprofen | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 24 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 23 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Scopolamine | Scopolamine | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | 14 |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 15 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 15 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 12 | 12 |
| Viibryd | Vilazodone Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $562.76 · 25 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AUSTEDO XR, CAPLYTA, COMIRNATY, CREON, Dexcom G6 Transmitter, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, KISUNLA, LINZESS, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, UBRELVY, Veozah, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error